Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific
stressors, occupies a central position in the development of novel anticancer treatments …

Accumulating evidence suggests that metabolic rewiring in malignant cells supports tumour
progression not only by providing cancer cells with increased proliferative potential and an …

Dendritic cells (DCs) are myeloid cells bridging the innate and adaptive immune system. By
cross‐presenting tumor‐associated antigens (TAAs) liberated upon spontaneous or therapy …

Combination therapy based on sonodynamic therapy (SDT) combined with immune
checkpoint blockers anti-PD-L1 provides effective anti-tumor effects. We designed a …

Chemotherapy is a cornerstone of cancer treatment, but it can also induce immune
suppression, which can have significant implications for patient outcomes. This review paper …

In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …

Dendritic cells (DCs) are professional antigen-presenting cells that play a key role in
shaping adaptive immunity. DCs have a unique ability to sample their environment, capture …

Cytotoxic anticancer therapies activate programmed cell death in the context of underlying
stress and inflammatory signaling to elicit the emission of danger signals, cytokines, and …

Immunotoxicity remains a major hindrance to chemotherapy in cancer therapy. Nanocarriers
may alleviate the immunotoxicity, but the optimal design remains unclear. Here, we created …